Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Equine Vet J ; 50(6): 831-835, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-29569401

RESUMO

BACKGROUND: Information on appropriate protocols for sedation of Nordestino donkeys is scarce. OBJECTIVES: To evaluate the sedative and cardiorespiratory effects of low doses of intravenous (i.v.) xylazine with and without acepromazine in 'Nordestino' donkeys. STUDY DESIGN: Seven healthy female Nordestino donkeys (150 ± 18 kg) were included in this blinded, randomised, crossover experiment. METHODS: Four treatments were administered, consisting of two i.v. injections, at baseline (T0, 1st injection) and 15 min later (T15, 2nd injection). Treatments included acepromazine 0.05 mg/kg bwt + saline (AS), saline + xylazine 0.5 mg/kg bwt (SX0.5), acepromazine + xylazine 0.25 mg/kg bwt (AX0.25) or acepromazine + xylazine 0.5 mg/kg bwt (AX0.5). Sedative and cardiorespiratory parameters were evaluated before T0 and 15, 20, 30, 45, 60, 75 and 90 min after treatment. Degree [height of head above ground (HHAG)] and quality of sedation [ataxia, responses to stimuli and visual analogue scale (VAS) scoring] and respiratory rate were evaluated by the main investigator in situ, and heart rate was measured by an assistant investigator. Three experienced evaluators assessed vídeos for ataxia and responses to stimuli. Normal data were analysed by repeated measures ANOVA, and non-normal by Kruskal-Wallis (P<0.05). RESULTS: HHAG was lower than baseline for 15 min after xylazine administration in AX0.25 and for 30 min in SX0.5 and AX0.5 groups. All treatments with xylazine increased VAS and ataxia scores in situ for 15 min after xylazine administration, with no differences between groups. Ataxia scores in situ were higher in SX0.5 and AX0.5 groups than AS for 15 and 30 min after xylazine administration, respectively. MAIN LIMITATIONS: Absence of a negative control group (saline-saline). CONCLUSION: Acepromazine added to xylazine at 0.25 mg/kg bwt produced briefer and milder sedation than xylazine at 0.5 mg/kg bwt.


Assuntos
Acepromazina/farmacologia , Agonistas de Receptores Adrenérgicos alfa 2/farmacologia , Equidae/fisiologia , Hipnóticos e Sedativos/farmacologia , Xilazina/farmacologia , Acepromazina/administração & dosagem , Agonistas de Receptores Adrenérgicos alfa 2/administração & dosagem , Animais , Estudos Cross-Over , Feminino , Frequência Cardíaca/efeitos dos fármacos , Hipnóticos e Sedativos/administração & dosagem , Injeções Intravenosas/veterinária , Distribuição Aleatória , Respiração/efeitos dos fármacos , Método Simples-Cego , Escala Visual Analógica , Xilazina/administração & dosagem
2.
Vet Comp Oncol ; 15(3): 793-807, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26879698

RESUMO

Transmissible venereal tumour (TVT) generally presents different degrees of aggressiveness, which makes them unresponsive to conventional treatment protocols. This implies a progressive alteration of their biological profile. This study aimed to evaluate the cytotoxicity, cell survival, apoptosis and cell cycle alterations in TVT cell cultures subjected to treatment with vincristine. Similarly, it assessed possible implications of MDR-1, TP53, BCL-2, and BAX gene expressions in eight TVT primary cultures for both resistance to chemotherapy and biological behaviour. When comparing TVT cells receiving vincristine to those untreated, a statistical difference related to increased cytotoxicity and decreased survival rates, and alterations in G1 and S cell cycle phases were found but without detectable differences in apoptosis. Increased MDR-1 gene expression was observed after treatment. The groups did not differ statistically in relation to the TP53, BAX and BCL-2 genes. Although preliminary, the findings suggest that such augmented expression is related to tumour malignancy and chemotherapy resistance.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Antineoplásicos Fitogênicos/uso terapêutico , Apoptose , Ciclo Celular , Doenças do Cão/patologia , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Proteína Supressora de Tumor p53/metabolismo , Tumores Venéreos Veterinários/patologia , Vincristina/uso terapêutico , Proteína X Associada a bcl-2/metabolismo , Animais , Apoptose/efeitos dos fármacos , Ciclo Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Doenças do Cão/tratamento farmacológico , Cães , Relação Dose-Resposta a Droga , Regulação Neoplásica da Expressão Gênica , Resultado do Tratamento , Tumores Venéreos Veterinários/tratamento farmacológico
3.
J Vet Intern Med ; 30(4): 941-50, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-27237065

RESUMO

BACKGROUND: Transpulmonary thermodilution (TPTDCO ) and calibrated pulse contour analysis (PCACO ) are alternatives to pulmonary artery thermodilution cardiac output (PATDCO ) measurement. HYPOTHESIS: Ten mL of ice-cold thermal indicator (TI10 ) would improve the agreement and trending ability between TPTDCO and PATDCO compared to 5 mL of indicator (TI5 ) (Phase-1). The agreement and TA between PCACO and PATDCO would be poor during changes in systemic vascular resistance (SVR) (Phase-2). ANIMALS: Eight clinically normal dogs (20.8-31.5 kg). METHODS: Prospective, experimental study. Simultaneous TPTDCO and PATDCO (averaged from 3 repetitions) using TI5 and TI10 were obtained during isoflurane anesthesia combined or not with remifentanil or dobutamine (Phase-1). Triplicate PCACO and PATDCO measurements were recorded during phenylephrine-induced vasoconstriction and nitroprusside-induced vasodilation (Phase-2). RESULTS: Mean bias (limits of agreement: LOA) (L/min), percentage bias (PB), and percentage error (PE) were 0.62 (-0.11 to 1.35), 16%, and 19% for TI5 ; and 0.33 (-0.25 to 0.91), 9%, and 16% for TI10 . Mean bias (LOA), PB, and PE were 0.22 (-0.63 to 1.07), 6%, and 23% during phenylephrine; and 2.12 (0.70-3.55), 43%, and 29% during nitroprusside. Mean angular bias (radial LOA) values were 2° (-10° to 14°) and -1° (-9° to 6°) for TI5 and TI10 , respectively (Phase-1), and 38° (5°-71°) (Phase-2). CONCLUSIONS AND CLINICAL IMPORTANCE: Although TI10 slightly improves the agreement and trending ability between TPTDCO and PATDCO in comparison to TI5 , both volumes can be used for TPTDCO in replacement of PATDCO . Vasodilation worsens the agreement between PCACO and PATDCO . Because of PCACO 's poor agreement and trending ability with PATDCO during SVR changes, this method has limited clinical application.


Assuntos
Débito Cardíaco/fisiologia , Cães/fisiologia , Artéria Pulmonar , Termodiluição/veterinária , Anestesia/veterinária , Animais , Feminino , Masculino , Monitorização Fisiológica/veterinária , Estudos Prospectivos , Termodiluição/métodos , Termodiluição/normas
4.
Vet Rec ; 164(12): 359-63, 2009 Mar 21.
Artigo em Inglês | MEDLINE | ID: mdl-19305006

RESUMO

Eighty-four female cats undergoing ovariohysterectomy in a blinded, randomised, prospective clinical study were assigned to one of three groups of 28 to receive either 0.01 mg/kg buprenorphine (group B), 4 mg/kg carprofen (group C), or the same doses of both drugs (group BC). A dynamic and interactive visual analogue scale (DIVAS) from 0 to 100 mm, and a simple descriptive scale (SDS) from 0 to 4 were used to evaluate the cats' degree of analgesia and sedation for 24 hours postoperatively. There was no significant difference in the cats' sedation scores by SDS or DIVAS, and no difference in their pain scores by DIVAS. By SDS, the cats in group BC had significantly lower pain scores than the cats in group C (P<0.001) and group B (P<0.05). Nine of the cats in group B, nine in group C and five in group BC required rescue analgesia, and the cats in group C required rescue earlier than those in group B (P<0.05).


Assuntos
Analgésicos Opioides/administração & dosagem , Anti-Inflamatórios não Esteroides/administração & dosagem , Buprenorfina/administração & dosagem , Carbazóis/administração & dosagem , Gatos , Dor Pós-Operatória/veterinária , Anestesia Geral/veterinária , Animais , Comportamento Animal/efeitos dos fármacos , Gatos/fisiologia , Gatos/cirurgia , Quimioterapia Combinada , Feminino , Histerectomia/métodos , Histerectomia/veterinária , Ovariectomia/métodos , Ovariectomia/veterinária , Medição da Dor/veterinária , Dor Pós-Operatória/tratamento farmacológico , Estudos Prospectivos , Fatores de Tempo , Resultado do Tratamento
5.
Vet Rec ; 162(26): 852-6, 2008 Jun 28.
Artigo em Inglês | MEDLINE | ID: mdl-18587062

RESUMO

To test the hypothesis that acepromazine could potentiate the sedative actions and attenuate the pressor response induced by dexmedetomidine, the effects of acepromazine or atropine were compared in six healthy adult dogs treated with this alpha2-agonist. In a randomised block design, the dogs received intravenous doses of either physiological saline, 0.05 mg/kg acepromazine or 0.04 mg/kg atropine, 15 minutes before an intravenous dose of 5 microg/kg dexmedetomidine. The dogs' heart rate was reduced by 50 to 63 per cent from baseline and their mean arterial blood pressure was increased transiently from baseline for 20 minutes after the dexmedetomidine. Atropine prevented the alpha2-agonist-induced bradycardia and increased the severity and duration of the hypertension, but acepromazine did not substantially modify the cardiovascular effects of the alpha2-agonist, except for a slight reduction in the magnitude and duration of its pressor effects. The dexmedetomidine induced moderate to intense sedation in all the treatments, but the dogs' sedation scores did not differ among treatments. The combination of acepromazine with dexmedetomidine had no obvious advantages in comparison with dexmedetomidine alone, but the administration of atropine before dexmedetomidine is contraindicated because of a severe hypertensive response.


Assuntos
Acepromazina/administração & dosagem , Adjuvantes Anestésicos/administração & dosagem , Atropina/administração & dosagem , Cães/fisiologia , Antagonistas de Dopamina/administração & dosagem , Acepromazina/farmacologia , Adjuvantes Anestésicos/farmacologia , Animais , Atropina/farmacologia , Gasometria/veterinária , Pressão Sanguínea/efeitos dos fármacos , Bradicardia/induzido quimicamente , Bradicardia/prevenção & controle , Bradicardia/veterinária , Estudos Cross-Over , Dexmedetomidina/administração & dosagem , Dexmedetomidina/farmacologia , Doenças do Cão/induzido quimicamente , Doenças do Cão/prevenção & controle , Antagonistas de Dopamina/farmacologia , Frequência Cardíaca/efeitos dos fármacos , Hipertensão/induzido quimicamente , Hipertensão/prevenção & controle , Hipertensão/veterinária , Hipnóticos e Sedativos/administração & dosagem , Hipnóticos e Sedativos/farmacologia
6.
Arq. bras. med. vet. zootec ; 59(2): 329-332, abr. 2007. tab
Artigo em Português | LILACS | ID: lil-455741

RESUMO

Foram avaliados os efeitos do propofol associado ao sufentanil sobre o balanço das atividades simpática e parassimpática do coração, investigando-se um possível efeito dose dependente do opióide. Analisou-se a variabilidade da freqüência cardíaca (VFC) de 12 cães adultos pré-medicados com maleato de acepromazina e anestesiados com propofol e três doses diferentes de sufentanil, que variou de 0,025 a 0,1µg/kg/min. Registrou-se o eletrocardiograma 15 minutos após a medicação pré-anestésica e 15, 30, 60, 90 e 120 minutos após a indução anestésica. A VFC foi calculada no domínio da freqüência, mediante análise de 10 intervalos RR consecutivos. Houve redução acentuada da freqüência cardíaca, mas a VFC permaneceu relativamente inalterada.


The effects of propofol and sufentanil on cardiac sympathetic and parasympathetic balance were studied, in order to evaluate if sufentanil plays a role in this balance. The heart rate variability of 12 adult dogs was assessed, after premedication with acepromazine and anesthetized with propofol and three different doses of sufentanil, ranging from 0.025 to 0.1µg/kg/min. Electrocardiograms were recorded 15 minutes after premedication and 15, 30, 60, 90, and 120 minutes after anesthetic induction. Heart rate variability was calculated in frequency domain through the analysis of 10 consecutive RR intervals. Results showed an absence of important changes in heart rate variability, although a significant decrease in heart rate was observed.


Assuntos
Animais , Feminino , Cães , Frequência Cardíaca , Propofol/administração & dosagem , Propofol/efeitos adversos , Sistema Nervoso Parassimpático/fisiologia , Sufentanil/administração & dosagem , Sufentanil/efeitos adversos
7.
Vet Rec ; 131(2): 33-5, 1992 Jul 11.
Artigo em Inglês | MEDLINE | ID: mdl-1509660

RESUMO

A combination of 0.5 mg/kg of methotrimeprazine, 0.1 mg/kg of midazolam and 100 mg/kg of a 10 per cent guaiphenesin solution was investigated for the induction of recumbency in 15 horses; the addition of 1.6 mg/kg of ketamine was also evaluated in 15 horses and anaesthesia was maintained with halothane in oxygen. The horses became recumbent quickly and smoothly and they recovered quietly, with little ataxia. Tachycardia occurred after induction, but no other changes from pre-operative values were observed until halothane in oxygen had been given, when hypothermia, hypotension, bradypnoea, hyperoxaemia, respiratory acidosis and decreased respiratory minute volume developed. Horses given ketamine in addition to methotrimeprazine, midazolam and guaiphenesin were easier to intubate and recovered more quickly than horses receiving only methotrimeprazine, midazolam and guaiphenesin.


Assuntos
Anestesia/veterinária , Guaifenesina , Hemodinâmica/efeitos dos fármacos , Cavalos/fisiologia , Ketamina , Metotrimeprazina , Midazolam , Respiração/efeitos dos fármacos , Animais , Temperatura Corporal/efeitos dos fármacos , Halotano , Pré-Medicação/veterinária
8.
Braz. j. vet. res. anim. sci ; 29(2): 251-6, 1992. tab
Artigo em Português | LILACS | ID: lil-128603

RESUMO

Foram utilizados 10 cäes adultos, de ambos os sexos, sem raça definida, com peso corpóreo entre 10 e 18 kg. Os animais foram pré-medicados com 1,0 mg/kg de levomepromazina e 15 minutos após receberam 2,0 mg/kg de midazolam, ambos por via intravenosa. A freqüência respiratória mostrou um aumento moderado e a freqüência cardíaca reduçäo aos 15 minutos e elevaçäo aos 30 minutos. Houve reduçäo da pressäo arterial média e da pressäo sistólica com significado estatístico e näo clínico. Houve tendência de reduçäo da pressäo arterial diastólica. A hipnose durou aproximadamente 20 minutos e aos 30 muinutos os cäes estavam acordados e em tentativa de deambulaçäo


Assuntos
Cães , Animais , Sistema Cardiovascular/efeitos dos fármacos , Metotrimeprazina/uso terapêutico , Midazolam/farmacologia , Pré-Medicação/veterinária , Anestesia
9.
J Electrocardiol ; 12(4): 381-6, 1979 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-512535

RESUMO

The Spatial Velocity (SV) represents the inscription velocity from spatial vectors of the QRS loop. According to Sano, this parameter has revealed a diagnostic capacity for some well defined pathologies. Using Hellerstein and Hamlin's formula, the SV has been determined from the orthogonal Frank leads in a 250 mm/sec recording. Using Simonson's criteria, 229 normal individuals, arranged in seven groups according to age and sex, were used in an attempt to get normal values for the second half of the QRS loop. SV was determined in six time intervals of 2.5 msec from the 25 msec vector before the end of QRS. We found significant difference between the values obtained from each time interval, except in the 35--37.5 msec and 37.5--40 msec vectors. On the other hand, no significant differences were found among the normal individual groups. The 96th percentile distribution was used to get the normal extreme values in the entire group of individuals.


Assuntos
Vetorcardiografia/métodos , Adulto , Idoso , Bloqueio de Ramo/diagnóstico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA